AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
13.7 C
New York
Wednesday, October 21, 2026

Tag: foundation

newsFORsourcecompanycontentinformation1releasesmarket

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

AES Stockholders Approve Acquisition by Global Infrastructure Partners and EQT-Led Consortium

ARLINGTON, Va., June 26, 2026 /PRNewswire/ -- The AES Corporation (the "Company" or "AES") (NYSE: AES) today announced that its stockholders voted to approve...

Revision Skincare® Appoints Marco Ficarelli as Chief Global Growth Officer

DALLAS, June 26, 2026 /PRNewswire/ -- Revision Skincare®, a physician-dispensed, clinically validated skincare brand focused on long-term skin health and medical-grade skincare for everyday use,...

Minister Hodgson advances Canadian Digital Core Library at EMMC 2026

YELLOWKNIFE, NT, June 26, 2026 /CNW/ - Canada is accelerating critical minerals development and building more resilient, diversified supply chains to create prosperity, jobs and...

After more than four decades of exceptional leadership and contribution to the fragrance industry, we announce the retirement of Jack Corley, Chief Sales and...

SOMERSET, N.J. , June 26, 2026 /PRNewswire/ -- Jack's career spans 45 years and is marked by a rare combination of commercial excellence, industry expertise,...

Scientology Network Presents Special Marathon for International Day Against Drug Abuse

LOS ANGELES, June 26, 2026 /PRNewswire/ -- As the world marks the UN's International Day Against Drug Abuse and Illicit Trafficking on June 26,...

The Inner Circle acknowledges Dr. Barbara Betancourt Cortes as a Pinnacle Lifetime Member

ROSWELL, Ga., June 26, 2026 /PRNewswire/ -- Dr. Barbara Betancourt Cortes is Recognized as a Pinnacle Lifetime Member for Excellence in Chiropractic Care and...

Kyivstar and VEON Partner with Ministry of Economy, Environment and Agriculture of Ukraine to Accelerate AI Infrastructure and Digital Economy Growth

This strategic initiative with the Ministry of Economy of Ukraine aims to fast-track digital infrastructure development, unlock scalable AI adoption, and underpin sustainable long-term economic growth.

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

CITGO Expresses Solidarity with the Venezuelan People and Mobilizes Humanitarian Assistance Following Devastating Earthquakes

HOUSTON, June 26, 2026 /PRNewswire/ -- CITGO Petroleum Corporation ("CITGO") expresses its deepest concern for the families of Venezuela who have been impacted by...

Autonomous Delivery Firm Neolix Expands European Presence as Retailers Fight Urban Logistics Costs

As FMCG and retail executives seek practical answers to last-mile economics, Neolix arrives with a commercial track recordVIENNA and FRANKFURT, Germany, June 26, 2026...

New Partnership Announced to Support OHV Recreation Access and Safety on Utah’s Iconic Bureau of Land Management Lands

SALT LAKE CITY, June 26, 2026 /PRNewswire/ -- A new partnership is funding projects to improve off-highway vehicle (OHV) access and riding areas across...

AI Tool Accelerates Joint Venture Identity Success

A proprietary AI brand diagnostic framework aligns three global executive teams on a joint venture identity in under six weeks. Here is how it...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFoundation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers